{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T15:15:53Z","timestamp":1780586153186,"version":"3.54.1"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100013671","name":"Sun Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013671","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s13555-026-01774-2","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T13:30:51Z","timestamp":1778333451000},"page":"3151-3165","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Tildrakizumab for Treatment of Moderate-to-Severe Scalp Psoriasis in Patients with Obesity Over 52 Weeks"],"prefix":"10.1007","volume":"16","author":[{"given":"Howard L.","family":"Sofen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranga","family":"Gogineni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tushar","family":"Nishandar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Bagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"issue":"8","key":"1774_CR1","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1001\/jamadermatol.2021.2007","volume":"157","author":"AW Armstrong","year":"2021","unstructured":"Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CEM. Psoriasis prevalence in adults in the United States. JAMA Dermatol. 2021;157(8):940\u20136.","journal-title":"JAMA Dermatol"},{"key":"1774_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.743180","volume":"8","author":"G Damiani","year":"2021","unstructured":"Damiani G, Bragazzi NL, Karimkhani Aksut C, et\u00a0al. The global, regional, and national burden of psoriasis: results and insights from the global burden of disease 2019 study. Front Med (Lausanne). 2021;8:743180.","journal-title":"Front Med (Lausanne)"},{"key":"1774_CR3","doi-asserted-by":"crossref","unstructured":"Menter A, Gottlieb A, Feldman SR, et\u00a0al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826\u201350.","DOI":"10.1016\/j.jaad.2008.02.039"},{"key":"1774_CR4","first-page":"139","volume":"12","author":"C Daugaard","year":"2022","unstructured":"Daugaard C, Iversen L, Hjuler KF. Comorbidity in adult psoriasis: considerations for the clinician. Psoriasis (Auckl). 2022;12:139\u201350.","journal-title":"Psoriasis (Auckl)"},{"issue":"6","key":"1774_CR5","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1159\/000455840","volume":"232","author":"P Jensen","year":"2016","unstructured":"Jensen P, Skov L. Psoriasis and obesity. Dermatology. 2016;232(6):633\u20139.","journal-title":"Dermatology"},{"issue":"4","key":"1774_CR6","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.jaad.2024.12.016","volume":"92","author":"J Burshtein","year":"2025","unstructured":"Burshtein J, Armstrong A, Chow M, et al. The association between obesity and efficacy of psoriasis therapies: an expert consensus panel. J Am Acad Dermatol. 2025;92(4):807\u201315.","journal-title":"J Am Acad Dermatol."},{"issue":"12","key":"1774_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/nutd.2012.26","volume":"2","author":"AW Armstrong","year":"2012","unstructured":"Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes. 2012;2(12):e54.","journal-title":"Nutr Diabetes"},{"issue":"10","key":"1774_CR8","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s40261-021-01080-z","volume":"41","author":"F Pirro","year":"2021","unstructured":"Pirro F, Caldarola G, Chiricozzi A, et\u00a0al. Impact of body mass index on the efficacy of biological therapies in patients with psoriasis: a real-world study. Clin Drug Investig. 2021;41(10):917\u201325.","journal-title":"Clin Drug Investig"},{"issue":"6","key":"1774_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103577","volume":"23","author":"J Wang","year":"2024","unstructured":"Wang J, Yu Y, Liu L, et\u00a0al. Global prevalence of obesity in patients with psoriasis: an analysis in the past two decades. Autoimmun Rev. 2024;23(6):103577.","journal-title":"Autoimmun Rev"},{"issue":"3","key":"1774_CR10","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1159\/000433528","volume":"231","author":"A Jacobi","year":"2015","unstructured":"Jacobi A, Langenbruch A, Purwins S, Augustin M, Radtke MA. Prevalence of obesity in patients with psoriasis: results of the national study PsoHealth3. Dermatology. 2015;231(3):231\u20138.","journal-title":"Dermatology"},{"issue":"11","key":"1774_CR11","first-page":"1","volume":"59","author":"A Czarnecka","year":"2023","unstructured":"Czarnecka A, Zablotna M, Purzycka-Bohdan D, Nowicki RJ, Szczerkowska-Dobosz A. An observational study of 147 psoriasis patients: overweightness and obesity as a significant clinical factors correlated with psoriasis. Medicina (Kaunas). 2023;59(11):1\u201313.","journal-title":"Medicina (Kaunas)"},{"issue":"10","key":"1774_CR12","first-page":"1947","volume":"13","author":"D Vata","year":"2023","unstructured":"Vata D, Tarcau BM, Popescu IA, et\u00a0al. Update on obesity in psoriasis patients. Life (Basel). 2023;13(10):1947.","journal-title":"Life (Basel)"},{"issue":"1","key":"1774_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ad.2012.08.003","volume":"105","author":"JM Carrascosa","year":"2014","unstructured":"Carrascosa JM, Rocamora V, Fernandez-Torres RM, et\u00a0al. Obesity and psoriasis: inflammatory nature of obesity, relationship between psoriasis and obesity, and therapeutic implications. Actas Dermosifiliogr. 2014;105(1):31\u201344.","journal-title":"Actas Dermosifiliogr"},{"issue":"4","key":"1774_CR14","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","volume":"80","author":"CA Elmets","year":"2019","unstructured":"Elmets CA, Leonardi CL, Davis DMR, et\u00a0al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019;80(4):1073\u2013113.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1774_CR15","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.jaad.2009.09.053","volume":"63","author":"S Bremmer","year":"2010","unstructured":"Bremmer S, Van Voorhees AS, Hsu S, et\u00a0al. Obesity and psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2010;63(6):1058\u201369.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1774_CR16","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/ced.12805","volume":"41","author":"JF Merola","year":"2016","unstructured":"Merola JF, Li T, Li WQ, Cho E, Qureshi AA. Prevalence of psoriasis phenotypes among men and women in the USA. Clin Exp Dermatol. 2016;41(5):486\u20139.","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"1774_CR17","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/bjd.17403","volume":"181","author":"M Augustin","year":"2019","unstructured":"Augustin M, Sommer R, Kirsten N, et\u00a0al. Topology of psoriasis in routine care: results from high-resolution analysis of 2009 patients. Br J Dermatol. 2019;181(2):358\u201365.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1774_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12895-020-00099-7","volume":"20","author":"A Egeberg","year":"2020","unstructured":"Egeberg A, See K, Garrelts A, Burge R. Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish skin cohort. BMC Dermatol. 2020;20(1):3.","journal-title":"BMC Dermatol"},{"issue":"4","key":"1774_CR19","doi-asserted-by":"publisher","first-page":"411","DOI":"10.2340\/00015555-1731","volume":"94","author":"F Sampogna","year":"2014","unstructured":"Sampogna F, Linder D, Piaserico S, et\u00a0al. Quality of life assessment of patients with scalp dermatitis using the Italian version of the Scalpdex. Acta Derm Venereol. 2014;94(4):411\u20134.","journal-title":"Acta Derm Venereol"},{"issue":"4","key":"1774_CR20","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","volume":"80","author":"A Menter","year":"2019","unstructured":"Menter A, Strober BE, Kaplan DH, et\u00a0al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029\u201372.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"1774_CR21","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jaad.2019.08.026","volume":"82","author":"B Strober","year":"2020","unstructured":"Strober B, Ryan C, van de Kerkhof P, et\u00a0al. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol. 2020;82(1):117\u201322.","journal-title":"J Am Acad Dermatol"},{"key":"1774_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.702776","volume":"8","author":"FM Ghazawi","year":"2021","unstructured":"Ghazawi FM, Mahmood F, Kircik L, et\u00a0al. A review of the efficacy and safety for biologic agents targeting IL-23 in treating psoriasis with the focus on tildrakizumab. Front Med (Lausanne). 2021;8:702776.","journal-title":"Front Med (Lausanne)"},{"key":"1774_CR23","unstructured":"ILUMYA\u00ae (tildrakizumab-asmn) injection, for subcutaneous use. Full Prescribing Information. Cranbury: Sun Pharmaceutical Industries, Inc.; 2024."},{"issue":"1","key":"1774_CR24","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jaad.2024.03.025","volume":"91","author":"K Gebauer","year":"2024","unstructured":"Gebauer K, Spelman L, Yamauchi PS, et\u00a0al. Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: a multicenter, randomized, double-blind, placebo-controlled, Phase 3b study. J Am Acad Dermatol. 2024;91(1):91\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1774_CR25","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/j.jaad.2024.12.018","volume":"92","author":"HL Sofen","year":"2025","unstructured":"Sofen HL, Gebauer K, Spelman L, et al. Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: Week 52 results from a Phase 3b, randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol. 2025;92(4):816\u201324.","journal-title":"J Am Acad Dermatol."},{"issue":"9","key":"1774_CR26","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1111\/j.1468-3083.2011.04065.x","volume":"25","author":"L Puig","year":"2011","unstructured":"Puig L. Obesity and psoriasis: body weight and body mass index influence the response to biological treatment. J Eur Acad Dermatol Venereol. 2011;25(9):1007\u201311.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1774_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0177175","volume":"12","author":"MG Swainson","year":"2017","unstructured":"Swainson MG, Batterham AM, Tsakirides C, Rutherford ZH, Hind K. Prediction of whole-body fat percentage and visceral adipose tissue mass from five anthropometric variables. PLoS ONE. 2017;12(5):e0177175.","journal-title":"PLoS ONE"},{"issue":"3","key":"1774_CR28","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1007\/s13679-024-00580-1","volume":"13","author":"K Sweatt","year":"2024","unstructured":"Sweatt K, Garvey WT, Martins C. Strengths and limitations of BMI in the diagnosis of obesity: what is the path forward? Curr Obes Rep. 2024;13(3):584\u201395.","journal-title":"Curr Obes Rep"},{"issue":"7","key":"1774_CR29","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1016\/j.numecd.2022.04.003","volume":"32","author":"AM Nevill","year":"2022","unstructured":"Nevill AM, Duncan MJ, Myers T. BMI is dead; long live waist-circumference indices: but which index should we choose to predict cardio-metabolic risk? Nutr Metab Cardiovasc Dis. 2022;32(7):1642\u201350.","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"1","key":"1774_CR30","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s40520-025-03197-z","volume":"37","author":"O Erdo\u011fan","year":"2025","unstructured":"Erdo\u011fan O, Erdo\u011fan T, \u00d6n\u00fcr NH, \u00d6zk\u00f6k S, Karan MA, Bahat G. Beyond BMI: central obesity measures and cardiovascular risk in late life. Aging Clin Exp Res. 2025;37(1):287.","journal-title":"Aging Clin Exp Res"},{"issue":"2","key":"1774_CR31","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/ijo.2011.100","volume":"36","author":"J G\u00f3mez-Ambrosi","year":"2012","unstructured":"G\u00f3mez-Ambrosi J, Silva C, Galofr\u00e9 JC, et\u00a0al. Body mass index classification misses subjects with increased cardiometabolic risk factors related to elevated adiposity. Int J Obes (Lond). 2012;36(2):286\u201394.","journal-title":"Int J Obes (Lond)"},{"key":"1774_CR32","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.metabol.2018.11.009","volume":"92","author":"C Iacobini","year":"2019","unstructured":"Iacobini C, Pugliese G, Blasetti Fantauzzi C, Federici M, Menini S. Metabolically healthy versus metabolically unhealthy obesity. Metabolism. 2019;92:51\u201360.","journal-title":"Metabolism"},{"issue":"8","key":"1774_CR33","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s40262-019-00743-7","volume":"58","author":"P Jauslin","year":"2019","unstructured":"Jauslin P, Kulkarni P, Li H, et\u00a0al. Population-pharmacokinetic modeling of tildrakizumab (MK-3222), an anti-interleukin-23-p19 monoclonal antibody, in healthy volunteers and subjects with psoriasis. Clin Pharmacokinet. 2019;58(8):1059\u201368.","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"1774_CR34","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1111\/bcp.14280","volume":"86","author":"T Kerbusch","year":"2020","unstructured":"Kerbusch T, Li H, Wada R, Jauslin PM, Wenning L. Exposure-response characterisation of tildrakizumab in chronic plaque psoriasis: pooled analysis of 3 randomised controlled trials. Br J Clin Pharmacol. 2020;86(9):1795\u2013806.","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"1774_CR35","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1111\/jdv.16187","volume":"34","author":"Y Poulin","year":"2020","unstructured":"Poulin Y, Ramon M, Rosoph L, et\u00a0al. Efficacy of tildrakizumab by patient demographic and disease characteristics across a Phase 2b and 2 Phase 3 trials in patients with moderate-to-severe chronic plaque psoriasis. J Eur Acad Dermatol Venereol. 2020;34(7):1500\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"1774_CR36","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1007\/s13555-022-00793-z","volume":"12","author":"D Thaci","year":"2022","unstructured":"Thaci D, Gerdes S, Du Jardin KG, Perrot JL, Puig L. Efficacy of tildrakizumab across different body weights in moderate-to-severe psoriasis over 5 years: pooled analyses from the reSURFACE pivotal studies. Dermatol Ther (Heidelb). 2022;12(10):2325\u201341.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"1","key":"1774_CR37","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1093\/bjd\/ljaf392","volume":"194","author":"MG Lebwohl","year":"2026","unstructured":"Lebwohl MG, Blauvelt A, Bagel J, Gogineni R, Griffiths CEM. Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis over 5 years in patients living with obesity. Br J Dermatol. 2026;194(1):172\u20134.","journal-title":"Br J Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01774-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-026-01774-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-026-01774-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T14:53:53Z","timestamp":1780584833000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-026-01774-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1774"],"URL":"https:\/\/doi.org\/10.1007\/s13555-026-01774-2","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"3 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Howard L. Sofen has served as a clinical investigator for AbbVie, Alumis, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant Sciences, Eli Lilly, Janssen, LEO Pharma, Novartis, Oruka Therapeutics, Sun Pharma, UCB, and Vyne Therapeutics. Ranga Gogineni is an employee of Sun Pharmaceutical Industries, Inc. Tushar Nishandar is an employee of Sun Pharmaceutical Industries Limited. Jerry Bagel has received research funds for the Psoriasis Treatment Center from AbbVie, Amgen, Arcutis Biotherapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Celgene Corporation, Corrona, Dermavant Sciences, Dermira, Glenmark Pharmaceuticals, Janssen, Kadmon Corporation, LEO Pharma, Lilly, Lycera, Menlo Therapeutics, Novartis, Ortho Dermatologics, Pfizer, Regeneron Pharmaceuticals, Sun Pharma, Taro Pharmaceutical Industries, and UCB; is or has been a consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene Corporation, Janssen, Lilly, Novartis, Sun Pharma, and UCB; and is or has been a speaker for AbbVie, Celgene Corporation, Eli Lilly, Janssen, and Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted in accordance with the principles of the Declaration of Helsinki. All patients provided written informed consent prior to the start of the study. The study protocol was approved by the independent ethics committee or institutional review board for each study site, as follows: Advarra IRB, SSU00080233, SSU00080197, SSU00084622, SSU00086947, SSU00084651, SSU00089424, SSU00087208, SSU00089759, SSU00089600, SSU00089741, SSU00094701, SSU00091780, SSU00092189, SSU00097078, SSU00097587, SSU00108132, SSU00099234, SSU00105498, SSU00105150, SSU00101234, and SSU00103922; Belberry Human Research Ethics Committee, 2019-06-529-A-3, 2019-06-529-A-5, and 2019-06-529-A-8.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}